Immunic (IMUX) Competitors $1.12 +0.03 (+2.75%) As of 01/7/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends IMUX vs. IGMS, SAGE, KMDA, VALN, CTNM, DSGN, YMAB, SLRN, NGNE, and TNGXShould you be buying Immunic stock or one of its competitors? The main competitors of Immunic include IGM Biosciences (IGMS), Sage Therapeutics (SAGE), Kamada (KMDA), Valneva (VALN), Contineum Therapeutics (CTNM), Design Therapeutics (DSGN), Y-mAbs Therapeutics (YMAB), Acelyrin (SLRN), Neurogene (NGNE), and Tango Therapeutics (TNGX). These companies are all part of the "pharmaceutical products" industry. Immunic vs. IGM Biosciences Sage Therapeutics Kamada Valneva Contineum Therapeutics Design Therapeutics Y-mAbs Therapeutics Acelyrin Neurogene Tango Therapeutics IGM Biosciences (NASDAQ:IGMS) and Immunic (NASDAQ:IMUX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, community ranking, profitability, analyst recommendations, risk, dividends and earnings. Do analysts prefer IGMS or IMUX? IGM Biosciences currently has a consensus price target of $17.75, suggesting a potential upside of 161.03%. Immunic has a consensus price target of $12.67, suggesting a potential upside of 1,030.95%. Given Immunic's stronger consensus rating and higher probable upside, analysts clearly believe Immunic is more favorable than IGM Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IGM Biosciences 1 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.50Immunic 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25 Is IGMS or IMUX more profitable? Immunic has a net margin of 0.00% compared to IGM Biosciences' net margin of -7,534.03%. IGM Biosciences' return on equity of -155.42% beat Immunic's return on equity.Company Net Margins Return on Equity Return on Assets IGM Biosciences-7,534.03% -155.42% -61.04% Immunic N/A -169.55%-118.96% Which has higher earnings & valuation, IGMS or IMUX? Immunic has lower revenue, but higher earnings than IGM Biosciences. IGM Biosciences is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIGM Biosciences$2.92M138.57-$246.42M-$3.64-1.87ImmunicN/AN/A-$93.61M-$1.23-0.91 Which has more risk and volatility, IGMS or IMUX? IGM Biosciences has a beta of 0.11, suggesting that its share price is 89% less volatile than the S&P 500. Comparatively, Immunic has a beta of 1.88, suggesting that its share price is 88% more volatile than the S&P 500. Does the media prefer IGMS or IMUX? In the previous week, Immunic had 5 more articles in the media than IGM Biosciences. MarketBeat recorded 6 mentions for Immunic and 1 mentions for IGM Biosciences. Immunic's average media sentiment score of 0.32 beat IGM Biosciences' score of -0.27 indicating that Immunic is being referred to more favorably in the news media. Company Overall Sentiment IGM Biosciences Neutral Immunic Neutral Do insiders and institutionals believe in IGMS or IMUX? 42.8% of IGM Biosciences shares are owned by institutional investors. Comparatively, 51.8% of Immunic shares are owned by institutional investors. 57.0% of IGM Biosciences shares are owned by insiders. Comparatively, 3.0% of Immunic shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community favor IGMS or IMUX? Immunic received 29 more outperform votes than IGM Biosciences when rated by MarketBeat users. Likewise, 65.16% of users gave Immunic an outperform vote while only 50.70% of users gave IGM Biosciences an outperform vote. CompanyUnderperformOutperformIGM BiosciencesOutperform Votes7250.70% Underperform Votes7049.30% ImmunicOutperform Votes10165.16% Underperform Votes5434.84% SummaryImmunic beats IGM Biosciences on 14 of the 18 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get Immunic News Delivered to You Automatically Sign up to receive the latest news and ratings for IMUX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMUX vs. The Competition Export to ExcelMetricImmunicPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$100.89M$6.63B$5.24B$9.03BDividend YieldN/A2.91%5.30%4.17%P/E Ratio-0.9110.4987.4817.23Price / SalesN/A202.371,105.99141.80Price / CashN/A57.1143.3337.88Price / Book1.755.175.185.13Net Income-$93.61M$153.18M$121.58M$227.03M7 Day Performance12.00%5.41%4.75%3.40%1 Month Performance-12.50%0.34%21.06%4.27%1 Year Performance-18.55%1.96%29.09%18.78% Immunic Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMUXImmunic2.4728 of 5 stars$1.12+2.8%$12.67+1,031.0%-19.4%$100.89MN/A-0.9170Analyst ForecastNews CoverageGap UpIGMSIGM Biosciences4.0574 of 5 stars$6.52-0.6%$17.75+172.2%-32.7%$387.71M$2.92M-1.79190SAGESage Therapeutics4.4422 of 5 stars$6.32+2.9%$10.53+66.6%-72.1%$386.61M$106.40M-1.13690Gap DownKMDAKamada4.2864 of 5 stars$6.63+2.8%$14.50+118.7%+14.3%$381.09M$158.38M23.68360News CoverageVALNValneva2.6402 of 5 stars$4.68+1.1%$18.50+295.3%-55.3%$380.30M$158.54M-36.00700Positive NewsCTNMContineum Therapeutics3.0952 of 5 stars$14.40-0.8%$29.25+103.1%N/A$371.20M$50M0.0031Positive NewsDSGNDesign Therapeutics1.2252 of 5 stars$6.53-2.0%$7.00+7.2%+134.9%$369.74MN/A-7.6840YMABY-mAbs Therapeutics2.3495 of 5 stars$8.14-0.4%$20.89+156.6%+6.5%$364.58M$84.55M-15.07150SLRNAcelyrin2.4967 of 5 stars$3.51-8.1%$11.75+234.8%-70.4%$352.14MN/A-1.43135Analyst ForecastNews CoveragePositive NewsGap DownNGNENeurogene3.138 of 5 stars$23.40+0.7%$60.83+160.0%-4.7%$347.61M$925,000.000.0090Gap DownTNGXTango Therapeutics2.183 of 5 stars$3.18+1.0%$13.14+313.3%-62.2%$341.59M$43.38M-2.6990Positive News Related Companies and Tools Related Companies IGM Biosciences Alternatives Sage Therapeutics Alternatives Kamada Alternatives Valneva Alternatives Contineum Therapeutics Alternatives Design Therapeutics Alternatives Y-mAbs Therapeutics Alternatives Acelyrin Alternatives Neurogene Alternatives Tango Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IMUX) was last updated on 1/8/2025 by MarketBeat.com Staff From Our PartnersDeFi Coin on Verge of Breakout!The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. Crypto 101 Media | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored#1 Crypto of 2025Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
